We canât show the full text here under this license. Use the link below to read it at the source.
Metabolic dysfunction-associated steatotic liver disease and heart failure with preserved ejection fraction: A state-of-the-art review
Fatty Liver Disease Linked to Metabolism Problems and Heart Failure with Normal Pumping Function
AI simplified
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) has become the leading cause of chronic liver disease globally.
- MASLD and heart failure with preserved ejection fraction (HFpEF) share common metabolic dysfunction as a foundational factor.
- There is a significant overlap in the underlying mechanisms of MASLD and HFpEF, including metabolic, inflammatory, and fibrotic pathways.
- The degree of hepatic fibrosis in MASLD is correlated with the prognosis and severity of HFpEF.
- Shared risk factors contribute to a strong bidirectional association between MASLD and cardiovascular diseases, especially HFpEF.
- Emerging treatments targeting both MASLD and HFpEF highlight the need for integrated care approaches.
AI simplified